MICRORNAS IN NEURODEGENERATIVE DISORDERS
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the rate of disease progression in a subject having a neurodegenerative disorder, selecting a subject for treatment of a neurodegenerative disorder, selecting a subject for participation in a clinical study, and determining the efficacy of treatment of a neurodegenerative disorder. These methods include determining the level of one or more microRNAs and/or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16− or CD14+CD16− monocyte) or in cerebrospinal fluid (CSF) from the subject and comparing the level of the one or more microRNAs and/or the level of the one or more inflammatory markers with a reference level(s). Also provided are methods of treating a neurodegenerative disorder that include administering to a subject at least one agent that decreases or increases the level or activity of one or more microRNAs or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16− or CD14+CD16− monocyte) or in the CSF of a subject.
-
Citations
40 Claims
-
1. (canceled)
-
2. A method of treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to a subject having ALS at least one antagomir comprising a sequence that is complementary to a contiguous sequence of at least 5 nucleotides present in microRNA hsa-miR-155.
- 3. A method of treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to a subject having ALS at least one inhibitory nucleic acid comprising a sequence that is complementary to a contiguous sequence of at least 5 nucleotides, present in microRNA hsa-miR-155.
-
12-22. -22. (canceled)
-
23. A method of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS), the method comprising:
-
determining a level of microRNA hsa-miR-155 in a CD14+CD16−
monocyte from the subject;comparing the level of hsa-miR-155 in a CD14+CD16−
monocyte from the subject to a reference level of the microRNA; andselecting a subject having an increase in the level of microRNA hsa-miR-155, in a CD14+CD16−
monocyte as compared to the reference level for treatment of ALS. - View Dependent Claims (27, 32, 33, 35, 36, 37, 38, 39)
-
-
24-26. -26. (canceled)
-
28. A method of selecting a subject for participation in a clinical study, the method comprising:
-
determining a level of microRNA hsa-miR-155 in a CD14+CD16−
monocyte from the subject;comparing the level of the microRNA hsa-miR-155 in a CD14+CD16−
monocyte from the subject to a reference level of the microRNAs; andselecting a subject having an increase in the level of microRNA hsa-miR-155, in a CD14+CD16−
monocyte as compared to the reference level for participation in a clinical study.
-
-
29-31. -31. (canceled)
-
34. (canceled)
Specification